PortalPublikationenChemotherapy is superior to checkpoint inhibitors after radi...

Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes

Standard

Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes. / Laukhtina, Ekaterina; Sari Motlagh, Reza; Mori, Keiichiro; Katayama, Satoshi; Rajwa, Pawel; Yanagisawa, Takafumi; Quhal, Fahad; Mostafaei, Hadi; Grossmann, Nico C; König, Frederik; Aydh, Abdulmajeed; Pradere, Benjamin; Resch, Irene; Merseburger, Axel S; Enikeev, Dmitry; Shariat, Shahrokh F.

in: CRIT REV ONCOL HEMAT, Jahrgang 169, 103570, 13.12.2021.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Laukhtina, E, Sari Motlagh, R, Mori, K, Katayama, S, Rajwa, P, Yanagisawa, T, Quhal, F, Mostafaei, H, Grossmann, NC, König, F, Aydh, A, Pradere, B, Resch, I, Merseburger, AS, Enikeev, D & Shariat, SF 2021, 'Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes', CRIT REV ONCOL HEMAT, Jg. 169, 103570. https://doi.org/10.1016/j.critrevonc.2021.103570

APA

Laukhtina, E., Sari Motlagh, R., Mori, K., Katayama, S., Rajwa, P., Yanagisawa, T., Quhal, F., Mostafaei, H., Grossmann, N. C., König, F., Aydh, A., Pradere, B., Resch, I., Merseburger, A. S., Enikeev, D., & Shariat, S. F. (2021). Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes. CRIT REV ONCOL HEMAT, 169, [103570]. https://doi.org/10.1016/j.critrevonc.2021.103570

Vancouver

Laukhtina E, Sari Motlagh R, Mori K, Katayama S, Rajwa P, Yanagisawa T et al. Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes. CRIT REV ONCOL HEMAT. 2021 Dez 13;169. 103570. https://doi.org/10.1016/j.critrevonc.2021.103570

Bibtex

@article{78c1bdac45c24d3b82d71e04889d9773,
title = "Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes",
abstract = "OBJECTIVE: To determine the oncologic and toxicity outcomes of adjuvant immunotherapy with immune checkpoint inhibitors (ICIs) compared to adjuvant chemotherapy in patients treated with radical surgery for urothelial carcinoma (UC).METHODS: We used the Bayesian approach in the network meta-analysis of different therapy regimens compared to observation or placebo.RESULTS: Nine studies comprised of 2,444 patients met the eligibility criteria. In bladder UC, chemotherapy, atezolizumab, and nivolumab did not improve disease progression compared to observation/placebo. In upper tract UC (UTUC), chemotherapy was significantly associated with a lower likelihood of disease progression compared to observation/placebo, while atezolizumab and nivolumab were not. Based on the analysis of the treatment ranking, adjuvant chemotherapy appeared as the best treatment approach in both bladder UC and UTUC. The risk of adverse events with ICIs was comparable to that of observation/placebo.CONCLUSION: Our analysis suggests a superior oncologic benefit to adjuvant chemotherapy over ICIs in patients treated with radical surgery for both bladder UC and UTUC.",
author = "Ekaterina Laukhtina and {Sari Motlagh}, Reza and Keiichiro Mori and Satoshi Katayama and Pawel Rajwa and Takafumi Yanagisawa and Fahad Quhal and Hadi Mostafaei and Grossmann, {Nico C} and Frederik K{\"o}nig and Abdulmajeed Aydh and Benjamin Pradere and Irene Resch and Merseburger, {Axel S} and Dmitry Enikeev and Shariat, {Shahrokh F}",
note = "Copyright {\textcopyright} 2021 The Author(s). Published by Elsevier B.V. All rights reserved.",
year = "2021",
month = dec,
day = "13",
doi = "10.1016/j.critrevonc.2021.103570",
language = "English",
volume = "169",
journal = "CRIT REV ONCOL HEMAT",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

RIS

TY - JOUR

T1 - Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes

AU - Laukhtina, Ekaterina

AU - Sari Motlagh, Reza

AU - Mori, Keiichiro

AU - Katayama, Satoshi

AU - Rajwa, Pawel

AU - Yanagisawa, Takafumi

AU - Quhal, Fahad

AU - Mostafaei, Hadi

AU - Grossmann, Nico C

AU - König, Frederik

AU - Aydh, Abdulmajeed

AU - Pradere, Benjamin

AU - Resch, Irene

AU - Merseburger, Axel S

AU - Enikeev, Dmitry

AU - Shariat, Shahrokh F

N1 - Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

PY - 2021/12/13

Y1 - 2021/12/13

N2 - OBJECTIVE: To determine the oncologic and toxicity outcomes of adjuvant immunotherapy with immune checkpoint inhibitors (ICIs) compared to adjuvant chemotherapy in patients treated with radical surgery for urothelial carcinoma (UC).METHODS: We used the Bayesian approach in the network meta-analysis of different therapy regimens compared to observation or placebo.RESULTS: Nine studies comprised of 2,444 patients met the eligibility criteria. In bladder UC, chemotherapy, atezolizumab, and nivolumab did not improve disease progression compared to observation/placebo. In upper tract UC (UTUC), chemotherapy was significantly associated with a lower likelihood of disease progression compared to observation/placebo, while atezolizumab and nivolumab were not. Based on the analysis of the treatment ranking, adjuvant chemotherapy appeared as the best treatment approach in both bladder UC and UTUC. The risk of adverse events with ICIs was comparable to that of observation/placebo.CONCLUSION: Our analysis suggests a superior oncologic benefit to adjuvant chemotherapy over ICIs in patients treated with radical surgery for both bladder UC and UTUC.

AB - OBJECTIVE: To determine the oncologic and toxicity outcomes of adjuvant immunotherapy with immune checkpoint inhibitors (ICIs) compared to adjuvant chemotherapy in patients treated with radical surgery for urothelial carcinoma (UC).METHODS: We used the Bayesian approach in the network meta-analysis of different therapy regimens compared to observation or placebo.RESULTS: Nine studies comprised of 2,444 patients met the eligibility criteria. In bladder UC, chemotherapy, atezolizumab, and nivolumab did not improve disease progression compared to observation/placebo. In upper tract UC (UTUC), chemotherapy was significantly associated with a lower likelihood of disease progression compared to observation/placebo, while atezolizumab and nivolumab were not. Based on the analysis of the treatment ranking, adjuvant chemotherapy appeared as the best treatment approach in both bladder UC and UTUC. The risk of adverse events with ICIs was comparable to that of observation/placebo.CONCLUSION: Our analysis suggests a superior oncologic benefit to adjuvant chemotherapy over ICIs in patients treated with radical surgery for both bladder UC and UTUC.

U2 - 10.1016/j.critrevonc.2021.103570

DO - 10.1016/j.critrevonc.2021.103570

M3 - SCORING: Review article

C2 - 34902554

VL - 169

JO - CRIT REV ONCOL HEMAT

JF - CRIT REV ONCOL HEMAT

SN - 1040-8428

M1 - 103570

ER -